3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Lymphoma
2
Stomatitis
1
Neuroendocrine Tumors
1
Neoplasms
1
Mucositis
1
Mouth Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Cisplatin
150
Radiotherapy
121
Cetuximab
96
Docetaxel
60
Fluorouracil
56
Paclitaxel
45
Radiotherapy, Intensity-Modulated
41
Carboplatin
40
pembrolizumab
34
Surveys and Questionnaires
22
Erlotinib Hydrochloride
19
Nivolumab
18
Immunohistochemistry
16
Gefitinib
16
Drug Therapy
16
Gemcitabine
14
Pemetrexed
13
Gene Expression Profiling
13
durvalumab
12
Chemotherapy, Adjuvant
12
Radiation
11
Filgrastim
11
Bevacizumab
11
Surgical Procedures, Operative
10
Polymerase Chain Reaction
10
Amifostine
10
Celecoxib
9
Capecitabine
9
Standard of Care
8
Neoadjuvant Therapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Head and Neck Neoplasms
×
RRx-001
×
Clear all
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts